NASDAQ:XNPT - XenoPort Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.07 +0.05 (+0.71 %)
(As of 05/23/2018 07:09 AM ET)
Previous Close$7.02
Today's Range$7.02 - $7.07
52-Week Range$3.35 - $7.86
Volume2.62 million shs
Average Volume1.22 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About XenoPort (NASDAQ:XNPT)

XenoPort logoXenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.

Receive XNPT News and Ratings via Email

Sign-up to receive the latest news and ratings for XNPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:XNPT
CUSIP98411C10
Phone+1-408-6167200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-103.12%
Return on Equity-414.36%
Return on Assets-37.19%

Miscellaneous

EmployeesN/A
Outstanding Shares63,520,000

XenoPort (NASDAQ:XNPT) Frequently Asked Questions

What is XenoPort's stock symbol?

XenoPort trades on the NASDAQ under the ticker symbol "XNPT."

How were XenoPort's earnings last quarter?

XenoPort, Inc. (NASDAQ:XNPT) issued its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02. The biopharmaceutical company earned $14.12 million during the quarter, compared to the consensus estimate of $14.24 million. XenoPort had a negative return on equity of 414.36% and a negative net margin of 103.12%. The company's revenue for the quarter was up 99.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. View XenoPort's Earnings History.

Has XenoPort been receiving favorable news coverage?

News coverage about XNPT stock has trended somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XenoPort earned a news sentiment score of 0.09 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.80 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of XenoPort?

Shares of XNPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XenoPort's stock price today?

One share of XNPT stock can currently be purchased for approximately $7.07.

How can I contact XenoPort?

XenoPort's mailing address is 2000 Seaport Blvd Ste 300, REDWOOD CITY, CA 94063-5584, United States. The biopharmaceutical company can be reached via phone at +1-408-6167200.


MarketBeat Community Rating for XenoPort (XNPT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about XenoPort and other stocks. Vote "Outperform" if you believe XNPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

XenoPort (NASDAQ:XNPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

XenoPort (NASDAQ:XNPT) Consensus Price Target History

Price Target History for XenoPort (NASDAQ:XNPT)

XenoPort (NASDAQ:XNPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

XenoPort (NASDAQ:XNPT) Earnings History and Estimates Chart

Earnings by Quarter for XenoPort (NASDAQ:XNPT)

XenoPort (NASDAQ XNPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2016Q116($0.21)($0.23)$14.24 million$14.12 millionViewN/AView Earnings Details
2/25/2016Q415($0.31)($0.21)$13.74 million$14.07 millionViewListenView Earnings Details
11/4/2015Q315($0.38)($0.38)$11.77 million$11.40 millionViewN/AView Earnings Details
8/5/2015Q215($0.32)($0.39)$9.77 million$8.60 millionViewN/AView Earnings Details
5/6/2015Q115($0.29)($0.33)$8.50 million$7.10 millionViewN/AView Earnings Details
2/19/2015Q414($0.34)($0.28)$7.10 million$7.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.36)$0.13$6.30 million$31.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.33)($0.31)$4.38 million$5.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.32)($0.36)$3.86 million$3.40 millionViewListenView Earnings Details
2/20/2014Q413($0.45)($0.40)$3.35 million$2.90 millionViewListenView Earnings Details
11/4/2013Q313($0.51)($0.39)$3.03 million$2.52 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.53)($0.51)$1.74 million$2.10 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.43)($0.50)$1.20 million$4.59 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.42)$0.07$1.02 million$0.49 millionViewN/AView Earnings Details
10/24/2012Q312($0.43)($0.41)$2.26 million$0.40 millionViewN/AView Earnings Details
8/7/2012($0.39)($0.22)ViewN/AView Earnings Details
5/2/2012($0.22)($0.26)ViewN/AView Earnings Details
2/14/2012($0.39)($0.48)ViewN/AView Earnings Details
11/2/2011($0.44)($0.55)ViewN/AView Earnings Details
8/3/2011($0.23)$0.55ViewN/AView Earnings Details
5/5/2011($0.49)($0.49)ViewN/AView Earnings Details
2/16/2011($0.62)($0.47)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.65)($0.65)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.61)($0.64)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.72)($0.75)ViewN/AView Earnings Details
2/22/2010Q4 2009($0.80)($0.60)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.76)($0.81)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.85)($0.76)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.31)($0.10)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.77)($0.74)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.35)($0.96)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.09)($0.49)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.05)($0.29)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.06)$0.09ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

XenoPort (NASDAQ:XNPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

XenoPort (NASDAQ XNPT) Insider Trading and Institutional Ownership History

Insider Trading History for XenoPort (NASDAQ:XNPT)
Insider Trading History for XenoPort (NASDAQ:XNPT)

XenoPort (NASDAQ XNPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/19/2016James E FlynnInsiderBuy20,973$3.99$83,682.27View SEC Filing  
2/12/2016James E FlynnInsiderBuy4,883,761$3.87$18,900,155.07View SEC Filing  
1/20/2016James E FlynnInsiderBuy346,417$4.09$1,416,845.53View SEC Filing  
9/1/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00191,703View SEC Filing  
7/15/2015Ronald W BarrettCEOSell12,500$7.20$90,000.00View SEC Filing  
7/13/2015Ronald W BarrettCEOSell12,500$7.00$87,500.00View SEC Filing  
5/11/2015Wendall WierengaDirectorBuy5,000$5.63$28,150.00View SEC Filing  
12/8/2014Gregory T BatesSVPSell14,166$8.35$118,286.10View SEC Filing  
12/8/2014Ronald W BarrettCEOSell7,015$8.36$58,645.40View SEC Filing  
12/5/2014Gianna M BoskoSVPSell60,000$8.45$507,000.00View SEC Filing  
9/9/2014Gregory T BatesSVPSell5,612$5.26$29,519.12View SEC Filing  
6/3/2014John Gordon FreundDirectorBuy12,500$3.93$49,125.00View SEC Filing  
5/27/2014Cathy FriedmanDirectorBuy2,600$3.92$10,192.00View SEC Filing  
5/23/2014John Gordon FreundDirectorBuy15,000$3.73$55,950.00View SEC Filing  
5/23/2014Ronald W BarrettCEOBuy2,600$3.75$9,750.00View SEC Filing  
5/15/2014Paul BernsDirectorSell2,500$3.66$9,150.005,000View SEC Filing  
4/24/2014Paul BernsDirectorSell2,500$4.30$10,750.002,500View SEC Filing  
6/14/2013Gregory T BatesSVPSell7,500$5.35$40,125.00View SEC Filing  
5/22/2013Ernest MarioDirectorBuy20,000$5.49$109,800.00View SEC Filing  
8/9/2012Ernest MarioDirectorBuy10,000$8.50$85,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

XenoPort (NASDAQ XNPT) News Headlines

Source:
DateHeadline
XenoPort (XNPT) and Aralez Pharmaceuticals (ARLZ) Head-To-Head AnalysisXenoPort (XNPT) and Aralez Pharmaceuticals (ARLZ) Head-To-Head Analysis
www.americanbankingnews.com - March 11 at 10:10 AM
Critical Comparison: Akorn (AKRX) & XenoPort (XNPT)Critical Comparison: Akorn (AKRX) & XenoPort (XNPT)
www.americanbankingnews.com - January 20 at 5:16 PM
Reviewing XenoPort (XNPT) and Its PeersReviewing XenoPort (XNPT) and Its Peers
www.americanbankingnews.com - January 19 at 5:32 PM
Head-To-Head Review: XenoPort (XNPT) vs. Its RivalsHead-To-Head Review: XenoPort (XNPT) vs. Its Rivals
www.americanbankingnews.com - January 3 at 3:36 PM
Critical Analysis: XenoPort (XNPT) vs. Its PeersCritical Analysis: XenoPort (XNPT) vs. Its Peers
www.americanbankingnews.com - January 2 at 3:16 PM
Financial Comparison: XenoPort (XNPT) versus Its CompetitorsFinancial Comparison: XenoPort (XNPT) versus Its Competitors
www.americanbankingnews.com - January 1 at 1:22 PM
Contrasting Teva Pharmaceutical Industries (TEVA) & XenoPort (XNPT)Contrasting Teva Pharmaceutical Industries (TEVA) & XenoPort (XNPT)
www.americanbankingnews.com - December 31 at 3:28 AM
Financial Review: XenoPort (XNPT) vs. Its RivalsFinancial Review: XenoPort (XNPT) vs. Its Rivals
www.americanbankingnews.com - December 24 at 5:34 PM
XenoPort (XNPT) & Its Peers Critical ReviewXenoPort (XNPT) & Its Peers Critical Review
www.americanbankingnews.com - December 23 at 7:34 AM
Head to Head Survey: XenoPort (XNPT) vs. Lannett Co (LCI)Head to Head Survey: XenoPort (XNPT) vs. Lannett Co (LCI)
www.americanbankingnews.com - November 22 at 5:24 PM
Critical Analysis: CoLucid Pharmaceuticals (CLCD) and XenoPort (XNPT)Critical Analysis: CoLucid Pharmaceuticals (CLCD) and XenoPort (XNPT)
www.americanbankingnews.com - October 9 at 8:10 AM
Arbor Pharma Announces Results of XenoPort (XNPT) Tender Offer - StreetInsider.comArbor Pharma Announces Results of XenoPort (XNPT) Tender Offer - StreetInsider.com
www.streetinsider.com - July 5 at 7:58 PM
XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure tXENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t
biz.yahoo.com - July 5 at 4:54 PM
XenoPort (XNPT) Enters MOU Over Pending Merger; Agrees to Make Additional DisclosuresXenoPort (XNPT) Enters MOU Over Pending Merger; Agrees to Make Additional Disclosures
www.streetinsider.com - June 28 at 8:20 PM
What Brexit Vote Could Mean for U.S. 2016 ElectionWhat Brexit Vote Could Mean for U.S. 2016 Election
www.marketwatch.com - June 22 at 6:52 PM
Arbor Pharmaceuticals, LLC -- Moodys Assigns B1 CFR to Arbor Pharmaceuticals; Stable OutlookArbor Pharmaceuticals, LLC -- Moody's Assigns B1 CFR to Arbor Pharmaceuticals; Stable Outlook
www.moodys.com - June 21 at 12:08 PM
Why Xenoport, Inc. Stock Jumped 61.1% in MayWhy Xenoport, Inc. Stock Jumped 61.1% in May
www.fool.com - June 4 at 9:04 AM
Arbor Pharma to Acquire XenoPort (XNPT) for $7.03/Share; Deal Valued at ~$467MArbor Pharma to Acquire XenoPort (XNPT) for $7.03/Share; Deal Valued at ~$467M
www.streetinsider.com - May 25 at 11:44 AM
Arbor Pharmaceuticals to buy XenoPort for $467MArbor Pharmaceuticals to buy XenoPort for $467M
www.bizjournals.com - May 25 at 11:44 AM
XenoPort Inc (XNPT) Stock Skyrockets on Arbor Merger AgreementXenoPort Inc (XNPT) Stock Skyrockets on Arbor Merger Agreement
www.bidnessetc.com - May 25 at 11:44 AM

SEC Filings

XenoPort (NASDAQ:XNPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

XenoPort (NASDAQ:XNPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

XenoPort (NASDAQ XNPT) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.